英文药名：Acofide（Acotiamide Hydrochloride Hydrate Tablets） 中文药名：盐酸阿考替胺片 生产厂家：安斯泰来制药 アコファイド錠100mg 治疗类别名称 功能性消化不良（FD）的治疗剂 批准日期：2013年6月 商標名 Acofide Tablets 通用名称 Akochiamido盐酸盐水合物（JAN） Acotiamide盐酸盐水合物（JAN） Acotiamide（INN） 化学名称 N-{2 - [双（1  - 甲基乙基）氨基]乙基} -2  - [（2  - 羟基-4,5 - 二甲氧基苯甲酰基）氨基]噻唑-4  - 甲酰胺盐酸盐三水合物 分子式 C21H30N4O5S·HCL·3H2O 分子量 541.06 结构式 性状 它是一种浅白色至黄色结晶粉末或晶体。的可溶性的N，N-二甲基甲酰胺，微溶于乙醇（99.5），甲醇，水，2-微溶于乙腈，丙醇，和极微溶于丙酮。几乎不溶于己烷和乙酸乙酯。 熔点 没有观察到熔点。 药效药理 1. 消化道机能亢进作用 表明提高狗的增强和大鼠餐后胃窦运动胃窦运动的影响。也显示出可乐定引起胃窦动力不足的狗和老鼠的改善效果 2、延迟胃排空改善作用 可乐定引起的延迟胃大鼠胃排空的改善效果。 3、作用机制。 乙酰胆碱酯酶的抑制作用 适应症 餐后的饱胀感，功能性消化不良，上腹部饱胀，早饱 用法与用量 成人，每天三次，每次100毫克饭前服。 包装规格 PTP包装　100錠（10錠×10），500錠（10錠×10×5） 制造厂商 泽里新药株式/安斯泰来制药公司 阿考替胺是日本安斯特莱斯制药公司与泽里新药株式会社联合开发的功能性消化不良（FD）治疗用药，于2013年6月6日率先在日本上市。 阿考替胺是全球第一个FD治疗用药，临床试验已经该药对于按照功能性胃肠道疾病诊断标准-ROME Ⅲ诊断为FD的患者具有良好的治疗有效性。阿考替胺系由泽里新药株式会社原研的一种新型的化学实体，该药抑制外周乙酰胆碱酯酶的活性。 乙酰胆碱是胃肠道活动性调节过程中起重要作用的神经递质，而阿考替胺正是通过抑郁乙酰胆碱的降解而改善受损的胃动力与滞后的胃的排空，并借此改善餐后饱胀感、上腹部胀气与过早饱感等诸多FD客观症状。 完整资料附件：http://www.info.pmda.go.jp/go/pack/2399015F1020_1_04/ Acofide Tablets（Acotiamide Hydrochloride Hydrate） Functional dyspepsia Even though there are stomach suspicions and stomach pain that doubt that there are ulcers and cancer in the stomach because of symptoms once called chronic gastritis, neurogenic gastritis, gastroptosis, stomach atonia, gastreb weakness Nevertheless, the symptom that the lesion can not be found even after the examination is called functional dyspepsia. One in four Japanese people is said to have functional dyspepsia and it is a familiar symptom. Causes include deterioration of gastric motility, stomach stretchability, stomach acid irritation, inflammation caused by Helicobacter pylori, brain sensitive sensation, and stress. As symptoms, there are two kinds of postprandial complaints syndrome in which feeling of leaning after meals or feeling of early satiety occurs more than a few times a week, epigastric pain syndrome (which can occur even on an empty stomach), which is likely to cause pain of the epigastrium or burning feeling. Zelia and Astellas, approved Zelia's new drug and Astellas have approved manufacturing and marketing from the Ministry of Health, Labor and Welfare for Zeria new drug for "Functional Dipeptia therapeutic agent" Acofide (R) tablet 100mg "(" Acofide (R) tablet " . This drug improves the reduction of gastric motility and the delay of food discharge from the stomach and improves the feeling of fullness after meal, the feeling of bloating fullness, and the feeling of satiety in the subjective symptoms. It is the first medicine to treat functional dyspepsia as indication, and will be launched in Japan ahead of the world. Dosage regimen/dose is orally administered once a day as an achothiamide hydrochloride hydrate 100 mg once a day before meals in adults